Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
3(20%)
Results Posted
71%(5 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_4
2
13%
Ph phase_1
1
7%
Ph phase_2
7
47%
Ph not_applicable
1
7%
Ph phase_3
2
13%

Phase Distribution

1

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
7(53.8%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
2(15.4%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

3

trials recruiting

Total Trials

15

all time

Status Distribution
Active(3)
Completed(7)
Terminated(1)
Other(4)

Detailed Status

Completed7
unknown3
Recruiting2
Active, not recruiting1
Terminated1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
3
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 27 (53.8%)
Phase 32 (15.4%)
Phase 42 (15.4%)
N/A1 (7.7%)

Trials by Status

active_not_recruiting17%
recruiting213%
completed747%
terminated17%
unknown320%
suspended17%

Recent Activity

3 active trials
Showing 5 of 15
recruitingphase_2

Etoricoxib in Patients With Parkinsonian Disease

NCT07370532
active_not_recruitingphase_2

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
recruiting

Substance Abuse Pre-Treatment Screening Study

NCT00439049
unknownphase_2

Improving Therapeutic Learning for PTSD

NCT04558112
completedphase_4

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07370532Phase 2

Etoricoxib in Patients With Parkinsonian Disease

Recruiting
NCT04469959Phase 2

Dopaminergic Dysfunction in Late-Life Depression

Active Not Recruiting
NCT00439049

Substance Abuse Pre-Treatment Screening Study

Recruiting
NCT04558112Phase 2

Improving Therapeutic Learning for PTSD

Unknown
NCT01770145Phase 4

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

Completed
NCT03761030Phase 4

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

Terminated
NCT04000919Phase 2

Effects of 5HTP and LDOPA on CNS Excitability After SCI

Suspended
NCT00537017Phase 2

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

Completed
NCT03754062Phase 1

Pharmacological Modulation of Belief Salience

Completed
NCT03891095Not Applicable

Oxytocin and Dopamine's Effect on Vicarious Optimism

Completed
NCT00406029Phase 2

Dyskinesia in Parkinson's Disease (Study P04501)

Completed
NCT01646255Phase 3

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

Completed
NCT01504178Phase 3

Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease

Completed
NCT02578849

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia

Unknown
NCT02347059Phase 2

L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15